Cumberland Pharmaceu (CPIX) Stock Price, Quote & News

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 255 0068

Fax: 615 255 0094

Website: www.cumberlandpharma.com

Address:

1600 West End Avenue, Suite 1300, Nashville, United States

OfficialStocktwitsUser Feb. 3 at 1:08 AM

$CPIX RSI: 27.37, MACD: -0.0124 Vol: 0.50, MA20: 4.35, MA50: 3.54 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BioResearcher Feb. 3 at 12:22 AM

$CPIX Nice volume ! This stock 's average daily volume has increased significantly after the cancer finding. very bullish sign.

1 · Reply

haha1978 Feb. 2 at 7:08 PM

$PBM $SUGP $CPIX IF we are going to PUMP SUGP take a look at CPIX. Consolidation is close to being done and its way over due for updates. Biotech run with a solid CEO so no dilution and it has 4 0 million in revenue and no RS.

1 · Reply

haha1978 Feb. 2 at 6:17 PM

$PBM $CPIX Check out CPIX if you want to see a tight 5 million share float after subtracting the CEO owning 45% and institutions owning 25%. Only 15 million issued and a 5 million float. No dilution or reverse splits in 20 years plus revenue.

0 · Reply

BioResearcher Feb. 1 at 2:38 PM

$CPIX One of reasons big pharma would love to own Ifetroban is the time to market can be very short. Big pharm can just need to run a phase 3 trial to bring this drug to the market to treat cancers:

0 · Reply

BioResearcher Jan. 30 at 9:07 PM

$CPIX Nice volume today ! Very bullish signal.

0 · Reply

BioResearcher Jan. 30 at 2:59 PM

$CPIX This is the ONLY small biotech company that I know can fully fund their trials with her own revenue stream. ZERO dilution for last 10 years. (OS stays constant for last 10 years) Management is A- TEAM, they execute plans lean and mean. Ifetroban will be a game changer for the company. It will be block-busters in many indications DMD Cardio, IPF, and cancers.

0 · Reply

WesleyVanguard3 Jan. 30 at 2:15 PM

$CPIX still a comer for me. When the market gets right, it will go up. My guess is March it will fly! 🚀

1 · Reply

haha1978 Jan. 30 at 5:25 AM

$CPIX maybe CPIX will participate for ifetroban. https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-precheck-implementation-roadmap

0 · Reply

haha1978 Jan. 29 at 8:21 PM

$TCGL $CPIX Wow TCGL has the same shares outstanding and a very similar float to CPIX. Gives me hope the difference is the 16% short position in the stock. Hope the shorts get wiped out. Good luck Longs I think you did great.

1 · Reply

CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT

Nov 4, 2025, 6:06 PM EST - 3 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 5:00 PM EST - 3 months ago

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Oct 28, 2025, 4:05 PM EDT - 3 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

Oct 20, 2025, 9:05 AM EDT - 3 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

RDHL

Oct 20, 2025, 9:00 AM EDT - 3 months ago

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Oct 13, 2025, 9:05 AM EDT - 4 months ago

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

Oct 1, 2025, 9:05 AM EDT - 4 months ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

Sep 29, 2025, 9:05 AM EDT - 4 months ago

TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

Aug 6, 2025, 1:52 AM EDT - 6 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 6 months ago

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

Aug 4, 2025, 9:05 AM EDT - 6 months ago

CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

Jul 29, 2025, 4:05 PM EDT - 6 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

Jun 23, 2025, 9:05 AM EDT - 8 months ago

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

May 27, 2025, 4:05 PM EDT - 9 months ago

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

May 13, 2025, 4:05 PM EDT - 9 months ago

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

May 10, 2025, 4:23 AM EDT - 9 months ago

Cumberland Pharmaceuticals, Inc. (CPIX) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 9 months ago

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

Apr 29, 2025, 4:05 PM EDT - 10 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

Mar 19, 2025, 4:05 PM EDT - 11 months ago

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Mar 4, 2025, 7:14 PM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

Feb 25, 2025, 4:05 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Feb 18, 2025, 7:30 AM EST - 1 year ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Feb 4, 2025, 1:31 PM EST - 1 year ago

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Feb 4, 2025, 7:30 AM EST - 1 year ago

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Dec 10, 2024, 12:08 PM EST - 1 year ago

Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?

Dec 9, 2024, 4:05 PM EST - 1 year ago

FDA APPROVES ACETADOTE® sNDA

Nov 9, 2024, 1:17 PM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Nov 6, 2024, 5:21 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Nov 5, 2024, 4:05 PM EST - 1 year ago

New Study Compares Caldolor® (ibuprofen injection) to ketorolac

Oct 31, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

Aug 11, 2024, 12:47 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024

Jul 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS

May 11, 2024, 11:51 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update

Apr 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Apr 2, 2024, 4:05 PM EDT - 2 years ago

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS

Mar 5, 2024, 10:06 PM EST - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results

Feb 27, 2024, 4:05 PM EST - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Nov 11, 2023, 8:17 AM EST - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

Oct 10, 2023, 4:05 PM EDT - 2 years ago

NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE

Aug 12, 2023, 4:21 AM EDT - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023

Aug 1, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS

OfficialStocktwitsUser Feb. 3 at 1:08 AM

0 · Reply

BioResearcher Feb. 3 at 12:22 AM

$CPIX Nice volume ! This stock 's average daily volume has increased significantly after the cancer finding. very bullish sign.

1 · Reply

haha1978 Feb. 2 at 7:08 PM

1 · Reply

haha1978 Feb. 2 at 6:17 PM

0 · Reply

BioResearcher Feb. 1 at 2:38 PM

$CPIX One of reasons big pharma would love to own Ifetroban is the time to market can be very short. Big pharm can just need to run a phase 3 trial to bring this drug to the market to treat cancers:

0 · Reply

BioResearcher Jan. 30 at 9:07 PM

$CPIX Nice volume today ! Very bullish signal.

0 · Reply

BioResearcher Jan. 30 at 2:59 PM

0 · Reply

WesleyVanguard3 Jan. 30 at 2:15 PM

$CPIX still a comer for me. When the market gets right, it will go up. My guess is March it will fly! 🚀

1 · Reply

haha1978 Jan. 30 at 5:25 AM

$CPIX maybe CPIX will participate for ifetroban. https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-precheck-implementation-roadmap

0 · Reply

haha1978 Jan. 29 at 8:21 PM

1 · Reply

BioResearcher Jan. 29 at 4:42 PM

$CPIX General market is crashing today.... Thanks for Microsoft. :-)

0 · Reply

BioResearcher Jan. 29 at 4:11 AM

$CPIX If Management decides to PR the recent breakthrough TNBC finding, this stock will be in double digits ! Wait for it !

1 · Reply

haha1978 Jan. 29 at 2:38 AM

$CPIX management never mentioned this study imo to surprise the market. Fingers crossed.

1 · Reply

haha1978 Jan. 29 at 2:27 AM

$CPIX Hopefully CPIX can partner with a BP for a P3 study if the results from the P2 is good for cancer metastasis prevention.

1 · Reply

haha1978 Jan. 29 at 2:19 AM

$CPIX well its only a 30 patient double blind p2 cancer metastasis study over 6 years. We will probably get the results in the next 3 months. I hope its true. They completed the study 4/2025.

0 · Reply

haha1978 Jan. 29 at 2:07 AM

$CPIX https://clinicaltrials.gov/study/NCT03694249?tab=study&a=15 If you read it looks like this ifetroban P2 study to treat cancer metasis will be completed 4/2026. Its a 6 year study. Or is this just an mistake? Im going to email the investigator at Vanderbilt.

0 · Reply

BioResearcher Jan. 28 at 9:04 PM

$CPIX Heavy volume today ! 260K shares on a nasty biotech day ! Be patient, folks....

0 · Reply

BioResearcher Jan. 28 at 8:53 PM

$CPIX To have a 20 folds gain stock is to get in early, where the potential is only known to a few, and no analysts pump. when it is invisible to Wall Street. CPIX fits my screening criteria.

0 · Reply

BioResearcher Jan. 28 at 7:21 PM

$CPIX This is just a small number of recent examples of Big pharm buying out promising preclinic can drugs:

0 · Reply

BioResearcher Jan. 28 at 6:07 PM

$CPIX This cancer market size is too big for big pharma to ignore. That is why big pharm love to buy any drug that has shown great efficacy in Preclinic settings. In case of Ifetroban, not only it has shown impressive efficacy, it has proven safe in human trials.

0 · Reply

BioResearcher Jan. 28 at 4:29 PM

$CPIX Ifetroban in cancer indication alone is targeting a $100+ billions treatment market !!! "The global metastatic cancer drugs market, valued between $67.7 billion and $108.1 billion in 2022–2023, is projected to reach over $136 billion to $168 billion by 2029–2032, with a CAGR ranging from 6% to 7.7%

0 · Reply

BioResearcher Jan. 28 at 4:00 PM

$CPIX Keep in mind that the Ifetroban 's breakthrough finding on TNBC treatment has been peer-reviewed and published on an well-known cancer journal. Also the study was from 2 universities that is independent of the Company. Those facts validate the integrity of the dataset. Big pharm will take notice.

0 · Reply

Market Cap	56.09M
Revenue (ttm)	37.87M
Net Income (ttm)	-6.48M
EPS (ttm)	N/A
PE Ratio	46.25
Forward PE	N/A
Profit Margin	-17.11%
Debt to Equity Ratio	0.20

Volume	228,300
Avg Vol	202,792
Day's Range	N/A - N/A
Shares Out	14.96M
Stochastic %K	21%
Beta	-0.53
Analysts	Strong Buy
Price Target	$8.50